Trends in HPV cervical and seroprevalence and associations between oral and genital infection and serum antibodies in NHANES 2003-2012

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Brouwer, Andrew F ^a   Eisenberg, Marisa C ^a   Carey, Thomas E ^a   Meza, Rafael ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Age Period Cohort modeling; HPV vaccine; Human papillomavirus; NHANES; Prevalence; Type concordant infection

Indexed keywords

ANTIBODY; WART VIRUS VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENITAL TRACT INFECTION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH INFECTION; PAPILLOMAVIRUS INFECTION; PHYSICAL EXAMINATION; RISK REDUCTION; SEROPREVALENCE; VACCINATION; WART VIRUS; AGED; BLOOD; MIDDLE AGED; MOUTH DISEASES; NUTRITION; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SEROEPIDEMIOLOGY; SEXUALLY TRANSMITTED DISEASES, VIRAL; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL DISEASES; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOUTH DISEASES; NUTRITION SURVEYS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL DISEASES; VACCINATION; YOUNG ADULT;

EID: 84953836829     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1314-0     Document Type: Article

References (43)

1. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. J Natl Cancer Inst. 2013; 105(3):175-201. doi: 10.1093/jnci/djs491.
2. Kreimer AR. Prospects for prevention of HPV-driven oropharynx cancer. Oral Oncol. 2014; 50(6):555-9. doi: 10.1016/j.oraloncology.2013.06.007.
3. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009; 10(4):321-2. doi: 10.1016/S1470-2045(09)70096-8.
4. International Agency for Research on Cancer. Human Papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2012; 100(B):255-96.
5. Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, et al. High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. JAMA Otolaryngol Head Neck Surg. 2013; 139(12):1320-7. doi: 10.1001/jamaoto.2013.5460.
6. Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012; 30 Suppl 5:34-54. doi: 10.1016/j.vaccine.2012.05.070.
7. Ho G, Bierman R. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338(7):423-8.
8. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999; 180(5):1415-23. doi: 10.1086/315086.
9. Molano M, van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, et al. Determinants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: A Population-based, 5-Year Follow-up Study. Am J Epidemiol. 2003; 158(5):486-94. doi: 10.1093/aje/kwg171.
10. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012; 30 Suppl 5:24-33. doi: 10.1016/j.vaccine.2012.05.089.
11. U.S. Food and Drug Administration. Human Papillomavirus Vaccine. http://www.fda.gov (2015). Accessed 12 Nov 2015.
12. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2014; 63(RR-05):1-30.
13. Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Singleton JA, Curtis CR, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years-United States, 2014. Morb Mortal Wkly Rep. 2015; 64(29):784-92.
14. Steinau M, Hariri S, Gillison ML, Broutian TR, Dunne EF, Tong Z, et al. Prevalence of cervical and oral human papillomavirus infections among US women. J Infect Dis. 2014; 209(11):1739-43. doi: 10.1093/infdis/jit799.
15. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study. J Infect Dis. 2010; 201(9):1331-9. doi: 10.1086/651620.
16. Lu B, Viscidi RP, Wu Y, Nyitray AG, Villa LL, Lazcano-Ponce E, et al. Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men. Cancer Epidemiol Biomarkers Prev. 2012; 21(9):1542-6. doi: 10.1158/1055-9965.EPI-12-0483.
17. Giuliano AR, Viscidi R, Torres BN, Ingles DJ, Sudenga SL, Villa LL, et al. Seroconversion following anal and genital HPV infection in men: The HIM study. Papillomavirus Research. 2015:1-7. doi: 10.1016/j.pvr.2015.06.007.
18. Holford TR. The Estimation of Age, Period and Cohort Effects for Vital Rates. Biometrics. 1983; 39(2):311-24.
19. Holford TR. Understanding the Effects of Age, Period, and Cohort on Incidence and Mortality Rates. Annu Rev Public Health. 1991; 12(1):425-57. doi: 10.1146/annurev.pu.12.050191.002233.
20. Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med. 1987; 6(4):449-67.
21. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med. 1987; 6(4):469-81.
22. Meza R, Pourbohloul B, Brunham RC. Birth cohort patterns suggest that infant survival predicts adult mortality rates. J Dev Orig Health Dis. 2010; 1(03):174-83. doi: 10.1017/S2040174410000218.
23. Holford TR, Levy DT, McKay LA, Clarke L, Racine B, Meza R, et al. Patterns of birth cohort-specific smoking histories, 1965-2009. Am J Prev Med. 2014; 46(2):31-7. doi: 10.1016/j.amepre.2013.10.022.
24. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006; 8034(36):19-25. doi: 10.1093/jncimonographs/lgj016.
25. Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci. 2002; 99(23):15095-100. doi: 10.1073/pnas.222118199.
26. Jeon J, Luebeck EG, Moolgavkar SH. Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control. 2006; 17(7):971-81. doi: 10.1007/s10552-006-0037-3.
27. Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Biomarkers Prev. 2009; 18(4):1092-100. doi: 10.1158/1055-9965.EPI-08-0976.
28. Anfinsen KP, Devesa SS, Bray F, Troisi R, Jonasdottir TJ, Bruland OS, et al. Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976-2005). Cancer Epidemiol Biomarkers Prev. 2011; 20(8):1770-7. doi: 10.1158/1055-9965.EPI-11-0136.
29. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013; 31(36):4550-9. doi: 10.1200/JCO.2013.50.3870.
30. Centers for Disease Control and Prevention, National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/nhanes.htm (2014). Accessed 13 Feb 2014.
31. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. J Am Med Assoc. 2007; 297(8):813-9. doi: 10.1001/jama.297.8.813.
32. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis. 2009; 200(7):1059-67. doi: 10.1086/604729.
33. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis. 2011; 204(4):566-73. doi: 10.1093/infdis/jir341.
34. Gillison ML, Broutian T, Pickard RKL, Tong Z-y, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009-2010. J Am Med Assoc. 2012; 307(7):693-703. doi: 10.1001/jama.2012.101.
35. Botman S, Moore T, Moriarty C, Parsons V. Design and Estimation for the National Health Interview, 1995-2004. Vital Health Stat 2. 2000; 130:1-31.
36. Aral SO, Patel Da, Holmes KK, Foxman B. Sexually transmitted diseases; 11:710-717. doi: 10.1097/01.olq.0000175370.08709.72.
37. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Advance data. 2005; 362:1-55.
38. Bajos N, Bozon M, Beltzer N, Laborde C, Andro A, Ferrand M, et al. Changes in sexual behaviours: from secular trends to public health policies. AIDS (London, England). 2010; 24(8):1185-1191. doi: 10.1097/QAD.0b013e328336ad52.
39. Liu G, Hariri S, Bradley H, Gottlieb SL, Leichliter JS, Markowitz LE. Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States. Sex Transm Dis. 2015; 42(1):20-6. doi: 10.1097/OLQ.0000000000000231.
40. Carter JJ, Koutsky La, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000; 181(6):1911-1919. doi: 10.1086/315498.
41. Edelstein ZR, Carter JJ, Garg R, Winer RL, Feng Q, Galloway DA, et al. Serum Antibody Response Following Genital a 9 Human Papillomavirus Infection in Young Men. 2011; 204:209-216. doi: 10.1093/infdis/jir242.
42. Mooij SH, Landén O, van der Klis FRM, van der Sande MAB, de Melker HE, Xiridou M, et al. HPV seroconversion following anal and penile HPV infection in HIV-negative and HIV-infected MSM. Cancer Epidemiol Biomarkers Prev. 2014; 23(11):2455-61. doi: 10.1158/1055-9965.EPI-14-0199.
43. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013; 208(3):385-93. doi: 10.1093/infdis/jit192.